Kneu Health, a precision neurology platform for Parkinson's and dementia, announced the close of a £4 million oversubscribed seed round. Co-led by Oxford Science Enterprises and Cedars-Sinai, with participation from Social Impact Enterprises, JIMCO, G.K. Goh Ventures and SXSW London, the funding will accelerate U.S. expansion by scaling Parkinson's deployments, expanding commercial capacity, and publishing outcomes data, while also advancing dementia monitoring. The round brings Kneu's total funding to date to over £8 million.
Neurological disorders are surging into a major public health crisis. Parkinson's is the fastest-growing neurological disease worldwide, while dementia cases are projected to triple by 2050. In the U.S., patients often wait many months between specialist visits, and neurologist shortages are leaving health systems unable to keep up with demand. The result is a care model that reacts too late, after decline has already accelerated, instead of providing the continuous support patients and families need.
Kneu's technology builds on more than a decade of longitudinal research, expanded with over 500,000 digital measures from 1,400+ users across NHS and U.S. deployments. Clinically trained AI models analyse speech, movement and cognition to generate predictive biomarkers that stratify risk across populations and guide targeted interventions. FDA clearance for smartphone-based Parkinson's tremor measurement affirms the platform's clinical rigour and enables proactive monitoring to be embedded directly into daily life and care pathways.
Clinicians report delivering better patient care, with 67% of cases achieving faster-than-standard access to treatment and data-driven insights supporting medication changes for over half of patients. Patients themselves report up to a 30% improvement in knowledge, confidence, and self-management—translating into greater independence and daily functioning. NHS pilots demonstrate the platform's ability to boost efficiency by 30%, reduce emergency admissions, and shift Parkinson's care from reactive to planned settings—equivalent to saving 1,000 bed days in a single provider.
With first contracts underway at Cedars-Sinai and Mass General Brigham and participation in the Global Incubator Programme at Texas Medical Center Innovation (TMCi), Kneu has established a presence in America's most influential medical ecosystems. Together, these efforts point to a larger shift: neurology can no longer rely on episodic care alone, and Kneu is showing that continuous data belongs at the centre of how health systems operate.
